nanology inhaled nanopac® preclinical study published in JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERy
(August 2019) — FT WORTH, (August 1, 2019) The preclinical study evaluated the antineoplastic and immunostimulatory effects of inhaled submicron particle paclitaxel (NanoPac) in an orthotopic non-small cell lung cancer rodent model. Tumor regression and immune cell infiltration were observed with an increased incidence noted in animals receiving NanoPac. An IND is in process to gain FDA authorization to begin a first-in-human clinical trial in early 2020. Click on the link below to read the full article.
Paul dorman named again to fort worth inc.’s the 400
(July 2019) — FT WORTH, (July/August, 2019 edition) Paul Dorman, CEO of long-successful DFB Pharmaceuticals, has been named again this year as an honoree in Fort Worth Inc.’s The 400. Please click on the link below and turn to page 66 in the Health Care and Life Sciences Section of the digital version of the magazine to read more.
NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
(May 2019) — FT WORTH, (May 14, 2019) NanOlogy LLC, a clinical-stage oncology company, announced today that its abstract showing encouraging therapeutic effects from a preclinical pharmacology study on inhaled NanoPac® (submicron particle paclitaxel) for treatment of lung cancer has been accepted for presentation at the 2019 American Thoracic Society International Conference. The abstract, entitled Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer (NSCLC), will be presented at the conference on May 20th, 11:15 AM to 1:00 PM, during the Oncogenic Mutations, Metastases, and Novel Therapeutics poster session at the Kay Bailey Hutchison Convention Center in Dallas. Click on the link below for event information.
Nanology presentation at drug development networking summit
(April 2019) — On April 11, 2019, Marc Iacobucci, managing director of DFB-affiliate NanOlogy, speaks at the Drug Development Summit in Bridgewater, NJ on the company’s submicron particle technology platform and progress on its clinical development in oncology. Click on the link below for event information.
usa today article: Americans are excited by medical innovation — healthcare exec Paul Dorman explains why
(March 2019) — After an extraordinarily successful career as an entrepreneur and investor, storied healthcare executive Paul Dorman was all set to retire. That was until he learned about advancements in submicron particle technology and what it could mean for more effective cancer treatments. Click on the link below to read the full article.
BIO CEO & Investor Conference 2019 Panel video
(February 2019) — NanOlogy chief medical officer, Gere diZerega, MD, participated in a panel discussion on “Reshaping Tumor Microenvironments via Immunotherapies” at the 2019 BIO CEO & Investor Conference in New York.
Nanology named as one of the Top 20 Life Science Startups to Watch in 2019
(January 2019) — NanOlogy was named as one of the top 20 life science start ups to watch in 2019 by BioSpace Inc., a leading digital news publication in life sciences and biotechnology.
dorman among 13 people in fort worth to watch in 2019
(January 2019) — Fort Worth Magazine named DFB Chairman and CEO, H. Paul Dorman, was one of 13 Fort Worthians to watch in 2019 based on progress of NanOlogy, a clinical-stage oncology company, he founded in 2015.
WuXI apptec article featuring ceo h. paul dorman: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
(November 2018) — NanOlogy CEO, H. Paul Dorman, had an opportunity to speak with WuXi Apptec, a leading development services and communication business with focus on China, on the combination of chemotherapies and immunotherapies to highlight the significance of small molecule drug development as an ongoing treatment modality. Click on the link below to read the full article.
Drug development & delivery article - Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
(September 2018) — NanOlogy published an article in the September issue of Drug Development with an update on its extensive preclinical and clinical development programs across three therapeutic areas and nine indications in cancer and related conditions. The company has now generated data on local delivery of its investigational drugs that are showing evidence of significant tumor reduction without the side effects associated with systemically administered chemotherapeutic agents. As importantly, the drugs are eliciting a strong immune response that may help sensitize the newer immunotherapies to increase their value in the treatment of cancer. Click on the link below to read the article.
DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
FT. WORTH/DALLAS, (September 18, 2018) — DFB Soria, a DFB Pharmaceuticals company, today announced completion of a dose-rising clinical trial of a topically applied submicron particle paclitaxel suspended in a pharmaceutically elegant, preservative-free anhydrous base. The trial was designed to evaluate safety and preliminary efficacy of four strengths of the product applied twice daily for 28 days. Results from the trial show evidence of AK lesion reduction in size and count, dose response, and minimal local irritation or other side effects.
NanOlogy™ presents preclinical lung data on nanopac® at ASCO Annual meeting in june
FT. WORTH/DALLAS, (June 15, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company, presented data at the ASCO Annual Meeting in June from preclinical studies of inhaled NanoPac (submicron particle paclitaxel) showing prolonged retention of drug in lung tissue and significant tumor regression without adverse drug-related observations in an orthotopic animal model of non-small cell lung cancer (NSCLC). Click on the link below to view the abstract.
NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
FT.WORTH/DALLAS, (April 30, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company, has completed the dose escalation phase of an open-label clinical trial of NanoPac (submicron particle paclitaxel sterile suspension) injected directly into the tumor area for treatment of prostate cancer. Successful completion of the dose escalation phase has allowed the highest concentration of NanoPac to begin the dose confirmation phase of the trial, which will continue to generate data on safety and tumor response.
Drug development & delivery EXECUTIVE INTERVIEW - NanOlogy: Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
(March 2018) — Demand for new cancer drugs is enormous with public and private investment skyrocketing for the latest technologies. Immuno-oncology therapies have captured much of the attention, and much of the investment, in recent years. The first generation of these drugs has offered some breakthroughs but not a panacea; and development of more effective, safer, and cost-effective therapies is still years away. Moreover, in patients for which immuno-oncology agents are indicated, oncologists frequently combine their use with traditional chemotherapeutics. Such combination use has been found to be synergistic but also, unfortunately, additive in systemic side effects. In the near term, increasing the safety and effectiveness of proven chemotherapies, such as paclitaxel and docetaxel, have the potential to improve the outlook for cancer patients much more quickly and cost-effectively. NanOlogy LLC, a clinical-stage pharmaceutical development company, is attempting to do just that by utilizing a breakthrough technology for producing unique, patented, naked submicron particles of paclitaxel and docetaxel.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial for Cutaneous Metastases and DFB Soria Provides an Update on AK Trial
DALLAS/FT.WORTH, (February 14, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, today announced enrollment of the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose escalating trial of three different strengths of the product will be followed by dose confirmation to evaluate safety and preliminary safety. NanOlogy has licensed the topical formulation for use in oncology from DFB Soria, which is owned and operated by DFB.
Phyton Biotech Unifies International Operations Under New Leadership
VANCOUVER, BC (December 21, 2017) —DFB announces the promotion of Colin Marr to President of Phyton Biotech, the world’s leader in commercial-scale plant cell fermentation technology and DFB’s wholly-owned subsidiary.
NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers
DALLAS/FT.WORTH, (December 18, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension administered intratumorally in patients with locally advanced pancreatic adenocarcinoma. The Phase 2a dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into the tumor by endoscopic ultrasound-guided fine needle injection in patients who have completed current standard of care treatment prior to trial entry. NanoPac is part of an extensive submicron technology platform developed by NanOlogy. Gere diZerega, MD, VP of Medical Affairs, will present an overview of the platform and an update of the clinical program at Biotech Showcase™, on January 8, 2018 at 3:45PM in Franciscan room D (Ballroom Level) of the Hilton San Francisco Union Square.
Phyton Biotech Wins Grant from Bill & Melinda Gates Foundation to Develop New Approaches to Manufacturing Artemisinin Pancreas
AHRENSBURG, Germany, (November 29, 2017) — Phyton Biotech today announced that it has received a $400,000 grant from the Bill & Melinda Gates Foundation to fund the research and development of an alternative method of producing artemisinin, a key active pharmaceutical ingredient (API) used to combat malaria. Artemisinin-based therapies are the global standard for the treatment of malaria, a disease that affects over 200 million people annually and is on the rise. The API is derived from the leaves of the herb Artemisia annua or sweet wormwood, a plant that is primarily harvested in Asia for the critical drug ingredient. With demand expected to continue to grow over the next twenty years, alternative methods of commercially producing the vital drug ingredient will be needed to ensure adequate, sustainable supply and stable prices.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas
DALLAS/FT.WORTH, (November 7, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension for treatment of mucinous cystic neoplasms (MCNs) of the pancreas. The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
DALLAS/FT.WORTH, (October 16, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension administered into the prostate for treatment of prostate cancer. Part of a broad nanoparticle technology platform developed by the company, NanoPac will be evaluated for safety and preliminary efficacy in a dose-rising Phase 2(a) clinical trial following intratumoral injection of the prostate via transrectal ultrasound guidance in patients four weeks prior to radical prostatectomy.
NanOlogy™Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer
DALLAS/FT.WORTH, (October 9, 2017) —NanOlogy LLC , a clinical-stage pharmaceutical development company, today announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac® (nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer. Part of a broad nanoparticle technology platform developed by the company, NanoPac will be evaluated for safety and efficacy after IP instillation of NanoPac at the end of cytoreductive (debulking) surgery.
NanOlogy™ to present at Bio investor forum on October 17, 2017 in san Francisco
DALLAS/FT.WORTH, (September 26, 2017) —NanOlogy™, a clinical-stage pharmaceutical development company, announced today that VP of Medical Affairs Gere diZerega, MD, will present at the BIO Investor Forum conference Tuesday, October 17 at 9:45 am at the Westin St. Francis in San Francisco. The presentation will cover the status of the company’s clinical development program and how its nanoparticle technology platform aims to transform systemic chemotherapy into local delivery of proven drugs.
DFB Soria gives update on enrollment of phase 2 clinical trial of sor007 (nanoparticle paclitaxel) ointment for actinic keratosis (AK)
DALLAS/FT.WORTH, (September 26, 2017) —DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, today announced completion of the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle paclitaxel formed by a proprietary production process. Identified as SOR007, the ointment is being evaluated topically in a dose escalating trial for safety and preliminary efficacy.
drug development and delivery article on formation of NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
September 14, 2017 – Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent years, but the first generation of these drugs has not delivered the hoped for panacea and development of more effective, safer immunotherapies is still years from reaching patients. In addition, immunotherapy is extremely expensive with treatment costs easily reaching $100,000 or more annually per patient.
DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
September 12, 2017 – DFB Pharmaceuticals, a private investment and development group, in collaboration with CritiTech and US Biotest, has formed NanOlogy to finance and develop a breakthrough technology platform to produce unique, patented, naked nanoparticle forms of paclitaxel and docetaxel for local delivery with the potential for greater efficacy and safety to treat cancer and other serious illnesses.
Texas Wesleyan and partners to honor Dorman at 48th Business Hall of Fame
July 7, 2017 – Texas Wesleyan University, the Fort Worth Business Press and the Fort Worth Chamber of Commerce are pleased to announce that Paul Dorman, CEO and chairman of DFB Pharmaceuticals, LLC, has been selected as the 2017 Fort Worth Business Executive of the Year.
Fort Worth entrepreneur, business executive provides tuition scholarships for new M.D. school
April 18, 2017 – In a show of support for the new TCU and UNTHSC School of Medicine, Fort Worth pharmaceutical executive, business investor and entrepreneur Paul Dorman will provide full first-year tuition to the inaugural class of medical students.
smith & nephew to acquire us bioactive wound care business for $782 million
November 28, 2012 – Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces that it is strengthening its global position in advanced wound care by entering into an agreement through its subsidiaries to acquire substantially all the assets of Healthpoint Biotherapeutics (“Healthpoint”), a leader in bioactive debridement, dermal repair and regeneration wound care treatments, for $782 million in cash.
Roundtable healthcare partners portfolio company, renaissance acquisition holdings, LLC Acquires dpt Laboratories
LAKE FOREST, IL, July 5, 2012 — RoundTable Healthcare Partners (“RoundTable”), an operating‐oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Renaissance Acquisition Holdings, LLC (“Renaissance”), has acquired DPT Laboratories Inc. (“DPT”).